Tpl2 Kinase Inhibitor 1 (Compound 1) is a potent and selective Tpl2 (COT kinase, MAP3K8) inhibitor that plays an important role in the regulation of the inflammatory response and the progression of some cancers[1].

CMPD1 is a selective inhibitor of non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation with apparent Ki (Kiapp) of 330 nM.

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc.

PF-3644022 is a potent, ATP-competitive inhibitor of mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) (IC50 = 5.2 nM and Ki = 3 nM). It inhibits tumor necrosis factor α (TNFα) production in U937 monocytic cells and peripheral blood mononuclear cells (PBMCs) (IC50 = 160 nM) and exhibits oral efficacy in acute and chronic inflammatory models.

MK2-IN-1 is a potent and selecitve MAPKAPK2 (MK2) inhibitor (IC50=0.11 μM) with a non-ATP competitive binding mode.